Healthcare stocks were edging higher premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) advancing by 0.4%.
BridgeBio Pharma (BBIO) stock was up more than 3% after the company said it met the primary endpoint in a phase 3 trial of the oral drug infigratinib, for the treatment of children living with achondroplasia, or bone dwarfism.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments